A NOVEL PD-L1-TARGETED SHARK VNAR SINGLE-DOMAIN-BASED CAR-T CELL STRATEGY FOR TREATING BREAST CANCER AND LIVER CANCER

Chimeric antigen receptor (CAR)-T cell therapy shows excellent potency against hematological malignancies, but it remains challenging to treat solid tumors, mainly because of a lack of appropriate antigenic targets and an immunosuppressive tumor microenvironment (TME).The checkpoint molecule programmed death-ligand 1 (PD-L1) is widely overexpressed

Introduction Since the beginning of the pandemic in 2020, COVID-19 has changed the medical landscape.International recommendations for localized prostate cancer (PCa) include deferred treatment and adjusted therapeutic routines.Materials and methods To longitudinally evaluate changes in PCa treatment strategies in urological and radiotherapy depart